Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | OGG1 | O15527 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028181 | 0.87 | BTN3A1 (0.40) | ALDH1A1HSD17B10KDM4EBTN3A1PGR | |
| SCHEMBL15487036 | 0.86 | ALDH1A1 (0.39) | ALDH1A1HSD17B10KDM4EBTN3A1PGR | |
| SCHEMBL1786739 | 0.84 | BTN3A1 (0.41) | ALDH1A1HSD17B10KDM4EBTN3A1PGR | |
| SCHEMBL15720921 | 0.84 | CYP2D6 (0.46) | ALDH1A1HSD17B10KDM4EBTN3A1PGR | |
| SCHEMBL12477823 | 0.83 | CNR2 (0.39) | ALDH1A1KDM4EBTN3A1CARM1PRMT6 | |
| SCHEMBL15708299 | 0.83 | ALDH1A1 (0.38) | ALDH1A1HSD17B10KDM4EBTN3A1PGR | |
| SCHEMBL722000 | 0.83 | KMT2A (0.40) | ALDH1A1HSD17B10KDM4EBTN3A1PGR | |
| SCHEMBL3977464 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KDM4EBTN3A1GAACARM1 | |
| SCHEMBL1027922 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KDM4EBTN3A1GAACARM1 | |
| SCHEMBL7027968 | 0.81 | BTN3A1 (0.40) | ALDH1A1BTN3A1HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658616-B2 | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-20110124592-A1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITUS C VIRUS | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124592-A1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITUS C VIRUS | PNP, NSUN2, MTAP | ALDH1A1 1292/4885HSD17B10 3824/4885KDM4E 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.